HUMAN PHYSIOLOGICAL AREAS

Metabolism and cardiovascular system

Carbohydrates, lipids, endothelium and liver: the area where you measure whether an ingredient really affects the mechanisms behind metabolic and cardiovascular wellbeing.

METABOLISM

What you can demonstrate here

If your product targets glycaemic control, the lipid profile, vascular protection or liver function, this is where the evidence supporting that promise is built. These are the mechanisms where the market is most crowded and most demanding: a comparative figure, on a relevant cell model, is what separates an ingredient from its competitor.

The models we use

HepatocytesHuman endothelial cellsAdipocytesEnteroendocrine cellsPancreatic beta cellsSkeletal muscle cellsIn vitro vessel modelsEnzyme assaysChemical-analytical methods

What we measure

Carbohydrate metabolism
  • Inhibition of alpha-amylase and alpha-glucosidase
  • Glucose uptake in hepatocytes and adipocytes
  • Anti-glycation activity
GLP-1, GIP and the gut-pancreas axis
  • GLP-1, GIP and PYY secretion from enteroendocrine cells
  • DPP-4 inhibition, cell-free and on intestinal epithelium
  • Glucose-stimulated insulin secretion by pancreatic beta cells treated with the digested ingredient
  • The path is staged: the pancreas axis or the microbiota arm starts only if the first phase passes an efficacy threshold agreed in advance.
Insulin resistance: liver, muscle, adipose tissue
  • Insulin-resistance models on hepatocytes, skeletal muscle cells and adipocytes, induced by excess lipids, glucose or inflammation
  • Insulin-stimulated glucose uptake, insulin signalling (Akt phosphorylation), GLUT4 translocation, lipid accumulation
  • In the liver model we also measure glucose production and release: in hepatocytes glucose transport is not directly insulin-dependent, so uptake alone does not show resistance
Lipid metabolism
  • Analysis of LDL receptors in hepatocytes
  • HMG-CoA reductase inhibition
  • Inhibition of LDL oxidation
  • Anti-lipogenic activity and fatty acid oxidation
Endothelium and vessel wall
  • Anti-inflammatory activity on endothelial cells
  • Cytoprotection of the endothelium from oxidative stress
  • Nitric oxide production
  • Vessel integrity and permeability in an in vitro model
  • Tubulogenesis and capillary reorganisation
Liver
  • Viability and cytoprotection of hepatocytes
  • Antioxidant activity in liver cells

What is measured in this area

Carbohydrates, lipids, endothelium and liver: the endpoints that show whether an ingredient acts on the mechanisms behind metabolic and cardiovascular wellbeing.

  • GLP-1, GIP and PYY secretion — the signal the gut sends the pancreas that glucose is arriving
  • DPP-4 inhibition — the enzyme that degrades GLP-1 and GIP
  • Insulin sensitivity — how liver, muscle and adipose tissue respond to insulin
  • Glucose uptake — glucose entering the cell, with and without stimulus
  • Lipid accumulation — lipids accumulated in adipocytes, quantified rather than estimated
  • Adipogenesis and lipolysis — adipocyte differentiation and lipid mobilisation
  • Endothelial function — endothelial cell response and nitric oxide production
  • Vascular oxidative stress — reactive species generated on the endothelium under stimulus
  • Inflammatory markers — cytokines released by endothelium and adipose tissue
  • Lipid metabolism enzymes — activity on lipases and on the enzymes involved in synthesis
  • Liver models — hepatocyte viability and function under the conditions tested

What you receive

  • A report with model, protocol, controls and raw data
  • Results per replicate, with mean and spread declared
  • Concentration-response curves on the chosen endpoints
  • A comparison between the stimulated condition and the control, which is the data that holds
  • A readable comparison between the conditions tested, usable in a technical dossier or in a conversation with a downstream customer

Who it is for, and where to start

How we can bring you value

You develop an ingredientand you want evidence your customers can useIngredient validation and valorisation
You develop a finished productand you want to know what stays active in the formulationSupplement valorisation and formulation development

Shall we talk about it?

Tell us about the product and what you need to show: we will tell you which models and which tests the case calls for.

Write to us

Tell us about your project

Write to us here: the division team will get back to you.